Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma

References

• Eggermont A, Robert C, Soria JC, Zitvogel L. Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. Oncoimmunology 2014; 3:e27560; PMID:24719793; http://dx.doi.org/10.4161/onci.27560
   PubMed Web of Science ®Google Scholar
• Speeckaert R, Van Geel N, Lambert J, Boone B, Chevolet I, Van Gele M, Speeckaert MM, Brochez L. Immune mediated mechanisms of melanocyte destruction: paving the way for efficient immunotherapeutic strategies against melanoma. Oncoimmunology 2012; 1:526-8; PMID:22754773; http://dx.doi.org/10.4161/onci.19403
   PubMed Web of Science ®Google Scholar
• Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012; 61:1019-31; PMID:22146893; http://dx.doi.org/10.1007/s00262-011-1172-6
   PubMed Web of Science ®Google Scholar
• Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5:200ra116; PMID:23986400
   PubMed Web of Science ®Google Scholar
• Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991; 5:2516-22; PMID:1907934
   PubMed Web of Science ®Google Scholar
• Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia SJ, Burgess R et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297:1867-70; PMID:12228717; http://dx.doi.org/10.1126/science.1073514
   PubMed Web of Science ®Google Scholar
• Johnson TS, Munn DH. Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. Immunol Invest 2012; 41:765-97; PMID:23017145; http://dx.doi.org/10.3109/08820139.2012.689405
   PubMed Web of Science ®Google Scholar
• Chevolet I, Speeckaert R, Haspeslagh M, Neyns B, Kruse V, Schreuer M, Van Gele M, Van Geel N, Brochez L. Peri-tumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control? Br J Dermatol 2014; 171:987-95; PMID:24814041; http://dx.doi.org/10.1111/bjd.13100
   PubMed Web of Science ®Google Scholar
• Speeckaert R, Vermaelen K, van Geel N, Autier P, Lambert J, Haspeslagh M, van Gele M, Thielemans K, Neyns B, Roche N et al. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur J Cancer 2012; 48:2004-11; PMID:22033321; http://dx.doi.org/10.1016/j.ejca.2011.09.007
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27:111-22; PMID:17629517; http://dx.doi.org/10.1016/j.immuni.2007.05.016
   PubMed Web of Science ®Google Scholar
• Khaled YS, Ammori BJ, Elkord E. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol 2013; 91:493-502; PMID:23797066; http://dx.doi.org/10.1038/icb.2013.29
   PubMed Web of Science ®Google Scholar
• Miwa N, Hayakawa S, Miyazaki S, Myojo S, Sasaki Y, Sakai M, Takikawa O, Saito S. IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-gamma increase in normal pregnancy but decrease in spontaneous abortion. Mol Hum Reprod 2005; 11:865-70; PMID:16421220; http://dx.doi.org/10.1093/molehr/gah246
   PubMed Web of Science ®Google Scholar
• Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J, Ren X. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 2013; 190:3783-97; PMID:23440412; http://dx.doi.org/10.4049/jimmunol.1201449
   PubMed Web of Science ®Google Scholar
• Weinlich G, Murr C, Richardsen L, Winkler C, Fuchs D. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 2007; 214:8-14; PMID:17191041; http://dx.doi.org/10.1159/000096906
   PubMed Web of Science ®Google Scholar
• Berthon C, Fontenay M, Corm S, Briche I, Allorge D, Hennart B, Lhermitte M, Quesnel B. Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification. Leuk Res 2013; 37:573-9; PMID:23453284; http://dx.doi.org/10.1016/j.leukres.2013.02.001
   PubMed Web of Science ®Google Scholar
• Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 2012; 13:e32-42; PMID:22225723; http://dx.doi.org/10.1016/S1470-2045(11)70155-3
   PubMed Web of Science ®Google Scholar
• Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3:1097-101; PMID:12368911; http://dx.doi.org/10.1038/ni846
   PubMed Web of Science ®Google Scholar
• Fujimura T, Kambayashi Y, Aiba S. Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth. Oncoimmunology 2012; 1:1433-4; PMID:23243619; http://dx.doi.org/10.4161/onci.21176
   PubMed Web of Science ®Google Scholar
• Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-48; PMID:11504745
   PubMed Web of Science ®Google Scholar
• Soichot M, Hennart B, Al Saabi A, Leloire A, Froguel P, Levy-Marchal C, Poulain-Godefroy O, Allorge D. Identification of a variable number of tandem repeats polymorphism and characterization of LEF-1 response elements in the promoter of the IDO1 gene. PLoS One 2011; 6:e25470; PMID:21980470; http://dx.doi.org/10.1371/journal.pone.0025470
   PubMedGoogle Scholar
• Raitala A, Pertovaara M, Karjalainen J, Oja SS, Hurme M. Association of interferon-gamma +874(T/A) single nucleotide polymorphism with the rate of tryptophan catabolism in healthy individuals. Scand J Immunol 2005; 61:387-90; PMID:15853924; http://dx.doi.org/10.1111/j.1365-3083.2005.01586.x
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 2013; 210:1389-402; PMID:23752227; http://dx.doi.org/10.1084/jem.20130066
   PubMed Web of Science ®Google Scholar
• Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gomez H, Bastholt L et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011; 9:204; PMID:22123319; http://dx.doi.org/10.1186/1479-5876-9-204
   PubMed Web of Science ®Google Scholar
• Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, Michielin O, Romano E, Speiser DE. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 2014; 63:247-57; PMID:24357148; http://dx.doi.org/10.1007/s00262-013-1508-5
   PubMed Web of Science ®Google Scholar
• Kitano S, Postow MA, Cortez C, Rasalan T, Gallardo HF, Panageas K, Yuan JD, Wolchok JD, Lesokhin AM. Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10 mg/kg to predict for overall survival in patients with metastatic melanoma. J Clin Oncol 2012; 30:2518.
   Google Scholar
• Schefold JC, Zeden JP, Fotopoulou C, von Haehling S, Pschowski R, Hasper D, Volk HD, Schuett C, Reinke P. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant 2009; 24:1901-8; PMID:19155537; http://dx.doi.org/10.1093/ndt/gfn739
   PubMed Web of Science ®Google Scholar
• Yamada K, Miyazaki T, Shibata T, Hara N, Tsuchiya M. Simultaneous measurement of tryptophan and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 867:57-61; PMID:18395499; http://dx.doi.org/10.1016/j.jchromb.2008.03.010
   PubMed Web of Science ®Google Scholar